Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
Information source: Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Leukemia
Intervention: Campath (Biological); rituximab (Biological); cyclophosphamide (Drug); fludarabine (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS Official(s) and/or principal investigator(s): Stephane Lepretre, MD, Study Chair, Affiliation: Centre Henri Becquerel Pierre Feugier, Principal Investigator, Affiliation: CHU de Nancy - Hopitaux de Brabois Roselyne DELEPINE, mrs, Study Director, Affiliation: Groupe Est Ouest Etudes leucemies et Autres Maladies du Sang
Summary
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in
different ways to kill cancer cells or stop them from growing. Monoclonal antibodies, such
as rituximab and alemtuzumab, can block cancer growth in different ways. Some find cancer
cells and help kill them or carry cancer-killing substances to them. Others interfere with
the ability of cancer cells to grow and spread. It is not yet known whether giving
fludarabine and cyclophosphamide together with rituximab is more effective than giving
fludarabine and cyclophosphamide together with alemtuzumab in treating B-cell chronic
lymphocytic leukemia.
PURPOSE: This randomized phase III trial is studying giving fludarabine together with
cyclophosphamide and rituximab to see how well it works as first-line therapy compared with
giving fludarabine together with cyclophosphamide and alemtuzumab in treating patients with
B-cell chronic lymphocytic leukemia.
Clinical Details
Official title: Randomized Phase-III Trial Comparing Fludarabine and Cyclophosphamide Plus Rituximab (FCR) to FC and MabCampath (FCCam) for Previously Untreated Fit Patients With Chronic Lymphocytic Leukemia (CLL)
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Progression-free survival at 36 months
Secondary outcome: Disease-free survivalEvent-free survival Overall survival Time to next treatment Overall response rate (complete response [CR] and partial response [PR]) Duration of phenotypic, molecular, NCI complete and partial responses Response rates and survival times in biological subgroups Treatment-related adverse effects
Detailed description:
OBJECTIVES:
Primary
- To compare 36-month progression-free survival in patients with Binet stage B or C
B-cell chronic lymphocytic leukemia treated with first-line therapy comprising
fludarabine phosphate and cyclophosphamide and either rituximab or alemtuzumab.
Secondary
- To compare the disease-free survival, event-free survival, and overall survival of
patients treated with these regimens.
- To compare time to next treatment in patients treated with these regimens.
- To compare the overall response rate (complete response [CR] and partial response [PR])
in patients treated with these regimens.
- To compare the rate of phenotypic and molecular response in patients treated with these
regimens.
- To compare the duration of phenotypic, molecular, complete and partial responses in
patients treated with these regimens.
- To compare the response rates and survival times in biological subgroups.
- To compare the rates of treatment-related adverse effects in patients treated with
these regimens.
- To compare the quality of life of patients treated with these regimens.
- Minimal residual disease study.
OUTLINE: This is a multicenter study. Patients are stratified according to Ig mutational
status and cytogenetic abnormalities. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive rituximab IV on day 1 and fludarabine phosphate and
cyclophosphamide IV or orally on days 2-4 of course 1. Beginning in course 2 and for
all subsequent courses, patients receive rituximab IV on day 1 and fludarabine
phosphate and cyclophosphamide IV or orally on days 1-3.
- Arm II: Patients receive alemtuzumab subcutaneously, oral fludarabine phosphate, and
oral cyclophosphamide on days 1-3.
In both arms, treatment repeats every 28 days for 6 courses in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 6 months.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
DISEASE CHARACTERISTICS:
Inclusion
Diagnosis of B-cell chronic lymphocytic leukemia (CLL), meeting the following criteria:
- Binet classification stages B or C
- Del 17 p (FISH) negative (< 10 % positives cores)
- Matutes score 4 or 5
Exclusion Transformation to aggressive B-cell malignancy (e. g. diffuse large cell
lymphoma, Hodgkin lymphoma, or prolymphocytic leukemia)
PATIENT CHARACTERISTICS:
Exclusion ECOG performance status ≥ 2
- Life expectancy < 6 months
- Creatinine clearance < 60 mL/min
- Total bilirubin > 2 x upper limit of normal (ULN)
- Gamma glutamyltransferase or transaminase levels > 2 x ULN
- Cumulative illness rating scale > 6
- HIV seropositivity
- Hepatitis B or C seropositivity (unless clearly due to vaccination)
- Clinically significant autoimmune anemia
- Active bacterial, viral, or fungal infection
- Active second malignancy currently requiring treatment (except basal cell carcinoma
or in situ endometrial carcinoma) and/or less than 5 years complete remission after
breast cancer
- Any severe comorbid conditions including, but not limited to, any of the following:
- Class III or IV heart failure
- Recent myocardial infarction
- Unstable angina
- Ventricular tachyarrhythmias requiring ongoing treatment
- Severe chronic obstructive pulmonary disease with hypoxemia
- Uncontrolled diabetes mellitus
- Uncontrolled hypertension
- Concomitant disease requiring prolonged use of corticosteroids (> 1 month)
- Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies
or any of the study drugs
- Contraindication to the use of rituximab or alemtuzumab according to Summary of
Product Characteristics
- Any coexisting medical or psychological condition that would preclude participation
in the required study procedures
- Any mental deficiency preventing proper understanding of the requirements of
treatment
- Person under law control
- Pregnant or breastfeeding women
- Fertile patients who cannot or do not wish to use an effective method of
contraception, during and for 12 months after the final treatment used for the
purposes of the study
PRIOR CONCURRENT THERAPY:
Inclusion
- No prior chemotherapy, radiotherapy, or immunotherapy for CLL
- Corticosteroids within the past month allowed
Locations and Contacts
Centre Henri Becquerel, Rouen 76038, France
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: November 2007
Last updated: July 24, 2013
|